TED
Can Ozempic End Addiction? | Dhruv Khullar | TED
Summarised with Bite · 8 min read
Dhruv Khullar uses one patient's startling experience with Ozempic to ask a much bigger question: could drugs built for diabetes and obesity also quiet addiction. The talk matters because it reframes addiction not just as a moral struggle, but as something deeply biological, while still warning that no medication can replace the harder social work of addressing trauma, loneliness, and inequality.
0:03 – 3:11
Mary notices the bar has gone quiet
A woman who could once drink 18 beers in a sitting walks into a bar and sees something she cannot explain: her heavy-drinking friend is barely touching her drink. That tiny moment becomes the spark for the whole talk. Dhruv Khullar introduces Mary, who started drinking at 13 and spent years trapped in the cycle of intoxication, hangover, rehab, Alcoholics Anonymous, and Antabuse, none of which worked for her. Then her friend mentions Ozempic, a drug Mary associated with obesity, not alcohol. Mary joins a clinical trial testing whether GLP-1 drugs could help with alcohol addiction. Each week, researchers blindfold her and inject either Ozempic or a placebo. Within weeks, her relationship to alcohol starts changing in stages. First she loses her taste for beer. Then she switches to white wine. Then she stops drinking altogether. Khullar borrows the now-common phrase that Ozempic can reduce "food noise," those repetitive thoughts about eating, and gives it a new twist. For Mary, the drug reduced "alcohol noise." What had felt like a commanding inner pressure became something she could finally observe from a distance. That distance mattered because it created room for other choices. She started exercising, improved her diet, and ended a difficult relationship. Her line is the emotional hinge of the section: "People know how much GLP-1s affect your body. I don't think they realize how much they affect your mind." Khullar then zooms out to explain why this story is so surprising. GLP-1 was discovered in the 1980s, but the natural molecule broke down too quickly to become a practical drug. The breakthrough came from an unexpected place, Gila monster venom, which contained a similar peptide that lasted for hours. What looked like obscure lizard research helped launch the modern GLP-1 era. That twist sets up the talk's central curiosity gap: if a drug built for metabolism can change desire itself, what else might it be doing in the brain?
2 more sections in the app
- 3:11 – 6:56The hunt for a moderation molecule
- 6:56 – 10:37From Aristotle to the hospital room
